Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction
- 30 September 1988
- journal article
- Published by Elsevier BV in American Journal Of Medicine
- Vol. 85 (3), 353-359
- https://doi.org/10.1016/0002-9343(88)90586-4
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJournal of the American College of Cardiology, 1988
- DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985
- Relation of effectiveness of intracoronary thrombolysis in acute myocardial infarction to systemic thrombolytic stateThe American Journal of Cardiology, 1985
- Human tissue-type plasminogen activator: from the laboratory to the bedside.Circulation, 1985
- Factors influencing probability of reperfusion with intracoronary ostial infusion of thrombolytic agent in patients with acute myocardial infarction.Circulation, 1985
- Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.Circulation, 1984
- Thrombolysis, clot selectivity, and kinetics.Circulation, 1984
- Hemorrhage and the products of fibrinogen digestion after intracoronary administration of streptokinase.Circulation, 1984
- Intracoronary thrombolysis in patients with acute myocardial infarction: comparison of the efficacy of urokinase with streptokinase.Circulation, 1984
- Systemic thrombolytic therapy of acute myocardial infarction?Circulation, 1983